Effects of antimuscarinic agents and prostaglandin E2 on the gastric mucosal lesions induced by necrotizing agents and water-immersion stress in rats.
スポンサーリンク
概要
- 論文の詳細を見る
The role of antimuscarinic action in gastric mucosal protection against necrotizing agents and the role of such mucosal protection in antiulcerogenic action were studied in rats with i.v. administered antimuscarinic agents. Pirenzepine, as well as PGE<SUB>2</SUB>, prevented the gastric mucosal lesions induced by all necrotizing agents (99.5% ethanol, 0.6 N HCl, 0.15 N NaOH, 0.4 N HCl-50 mM taurocholate), but atropine did not prevent the HCl-induced lesions. Cimetidine inhibited only the ethanol-induced lesions even at the antisecretory dose. Higher doses of pirenzepine (5-fold) and atropine (10-fold) were required to inhibit the gastric secretion in Shay rats than in vagally stimulated rats. There was no difference between the antisecretory doses of cimetidine in Shay rats and vagally stimulated rats. PGE<SUB>2</SUB> (0.03-0.1 mg/kg) did not affect gastric secretion. The protective doses of pirenzepine and atropine against mucosal lesions induced by necrotizing agents were similar to the dose in inhibiting vagally stimulated acid secretion and water-immersion stress-induced lesions. PGE<SUB>2</SUB> (100 μg/kg) did not prevent the water-immersion stress induced gastric lesions. These results suggested that antimuscarinic agents protect the gastric mucosa from necrotizing agents via a blocking action on the activation of the intrinsic cholinergic nerve. However, antiulcerogenic action is more deeply concerned with antisecretory action than cytoprotection.
- 公益社団法人 日本薬理学会の論文
著者
-
HAYASHI Toshihiro
Nippon Boehringer Ingelheim Co., Ltd., Kawanishi Pharma Resarch Institute
-
KITAGAWA Hisato
Nippon Boehringer Ingelheim Co., Ltd., Kawanishi Pharma Resarch Institute
-
TAKEDA Fumiyo
Nippon Boehringer Ingelheim Co., Ltd., Kawanishi Pharma Resarch Institute
-
KINEKAWA Fumihiko
Nippon Boehringer Ingelheim Co., Ltd., Kawanishi Pharma Resarch Institute
-
KOHEI Hiroshi
Nippon Boehringer Ingelheim Co., Ltd., Kawanishi Pharma Resarch Institute